Kawano et al., 2021 - Google Patents
Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and …Kawano et al., 2021
- Document ID
- 3269401246431587857
- Author
- Kawano M
- Tsuchiya J
- Bae H
- Kimura K
- Yokoyama K
- Takahashi M
- Honda M
- Tominaga M
- Tateishi U
- Publication year
- Publication venue
- Annals of Nuclear Medicine
External Links
Snippet
Objectives NMB58 is a novel positron emission tomography (PET) tracer containing flurpiridaz as an active ingredient and available as a myocardial perfusion imaging tracer that targets mitochondrial complex 1. A phase I clinical study of NMB58 was conducted to …
- 238000002600 positron emission tomography 0 title abstract description 36
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computerised tomographs
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/504—Clinical applications involving diagnosis of blood vessels, e.g. by angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ouchi et al. | Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (ewtopia 75) A randomized, controlled trial | |
| Maddahi et al. | Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest | |
| Labbé et al. | Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans | |
| Brown et al. | Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation | |
| Wagner et al. | Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study | |
| Chen et al. | Positron emission tomography with [18F] fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury | |
| Mahnken et al. | Quantitative whole heart stress perfusion CT imaging as noninvasive assessment of hemodynamics in coronary artery stenosis: preliminary animal experience | |
| Hjørnevik et al. | Biodistribution and radiation dosimetry of 18F-FTC-146 in humans | |
| Asano et al. | Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18 F] FACBC | |
| Maddahi et al. | Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging | |
| Tadamura et al. | Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men | |
| Zhu et al. | Biodistribution and radiation dosimetry of the Enterobacteriaceae-specific imaging probe [18 F] fluorodeoxysorbitol determined by PET/CT in healthy human volunteers | |
| Schierz et al. | Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions | |
| Koole et al. | Preclinical safety evaluation and human dosimetry of [18 F] MK-6240, a Novel PET tracer for imaging neurofibrillary tangles | |
| Foss et al. | Biodistribution and radiation dosimetry of 124I-DPA-713, a PET radiotracer for macrophage-associated inflammation | |
| Hines et al. | Propofol decreases in vivo binding of 11C-PBR28 to translocator protein (18 kDa) in the human brain | |
| Blasi et al. | Radiation dosimetry of the fibrin-binding probe 64Cu-FBP8 and its feasibility for PET imaging of deep vein thrombosis and pulmonary embolism in rats | |
| Yang et al. | Arterial CO2 as a potent coronary vasodilator: a preclinical PET/MR validation study with implications for cardiac stress testing | |
| Brier et al. | Phase 1 evaluation of 11C-CS1P1 to assess safety and dosimetry in human participants | |
| Alameen et al. | Radiobiological risks in terms of effective dose and organ dose from 18F-FDG whole-body PET/CT procedures | |
| Rischka et al. | First-in-humans brain PET imaging of the GluN2B-containing N-methyl-d-aspartate receptor with (R)-11C-Me-NB1 | |
| Ruiz-Bedoya et al. | 11C-PABA as a PET radiotracer for functional renal imaging: Preclinical and first-in-human study | |
| Schechter et al. | Radiation dosimetry and biodistribution of 99m Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer | |
| van Leer et al. | Practice of 18F-FDG-PET/CT in ICU patients: a systematic review | |
| Pelletier‐Galarneau et al. | Randomized trial comparing the effects of ticagrelor versus clopidogrel on myocardial perfusion in patients with coronary artery disease |